In a phase 1 trial of 10 people with moderate-to-advanced Parkinson's, a brain-infused gene therapy caused no dose-limiting toxicities over 12 months. A safety result, not yet proof it eases symptoms
Peer-reviewed · Nature medicine · n=10 · 17 June 2026
The Cambridge-built shot triggered immune responses against SARS-CoV-2, SARS and bat viruses that haven't yet infected people, aiming to work even as the virus mutates.
Peer-reviewed · Journal of Infection / University of Cambridge & DIOSynVax (DVX) Ltd; funded by Innovate UK · n=39 · 12 June 2026
Disabling a single protein, NFIL3, kept CAR-T cells fighting longer and controlled tumors better in mice, pointing to a possible fix for the solid cancers the therapy has struggled to treat.
Peer-reviewed · Cancer Discovery / Columbia University & University Hospital Tübingen · 12 June 2026
The FDA granted accelerated approval to the first gene therapy for inherited deafness; in its trial, 80% of 20 evaluable children gained hearing a result not seen in this condition untreated.
Peer-reviewed · New England Journal of Medicine · n=24 · 16 June 2026
Canadian scientists identified SLAMF6, an internal "brake" that exhausts cancer-fighting T cells on its own, and built antibodies to release it, boosting tumor attacks in mice.
Peer-reviewed · Nature / Montreal Clinical Research Institute (IRCM), Université de Montréal · 12 June 2026
In a 24-patient Phase 2a trial, an mRNA molecule injected into damaged heart muscle improved the heart's pumping function at three months, the first human evidence that mRNA can trigger cardiac repai
Peer-reviewed · Nature · n=24 · 11 June 2026